|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
EBOOKCENTRAL_ocn935255331 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
160123s2015 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d RECBK
|d OCLCQ
|d MERUC
|d ZCU
|d ICG
|d OCLCO
|d OCLCF
|d OCLCQ
|d WYU
|d DKC
|d OCLCQ
|d SGP
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 020 |
|
|
|a 9781118849569
|
| 020 |
|
|
|a 1118849566
|
| 029 |
1 |
|
|a AU@
|b 000058380809
|
| 029 |
1 |
|
|a DEBBG
|b BV043627939
|
| 035 |
|
|
|a (OCoLC)935255331
|
| 050 |
|
4 |
|a RC78.7.D53
|b O283 2015
|
| 060 |
1 |
0 |
|a WN 180
|
| 082 |
0 |
4 |
|a 616.0754
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Obuchowski, Nancy A.
|
| 245 |
1 |
0 |
|a Handbook for Clinical Trials of Imaging and Image-Guided Interventions.
|
| 260 |
|
|
|b Wiley,
|c 2015.
|
| 300 |
|
|
|a 1 online resource (226 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Title Page ; Copyright Page; Contents; Contributors; Chapter 1 Imaging technology assessment; 1.1 Six levels of evidence: a model of technology assessments in imaging; 1.1.1 Level 1: technical efficacy; 1.1.2 Level 2: diagnostic accuracy; 1.1.3 Levels 3 and 4: impact on diagnostic thinking and therapeutic planning; 1.1.4 Level 5: patient outcomes; 1.1.5 Level 6: societal efficacy; 1.2 Case examples: introducing technology assessment methods into study design; 1.3 Conclusion; References; CHAPTER 2 Clinical trials of therapy; 2.1 Phases I, II, and III: their goals and rationale.
|
| 505 |
8 |
|
|a 2.2 Therapeutic roles: prevention, cure, and palliation2.3 Roles of different modalities; 2.3.1 Surgery; 2.3.2 Radiation therapy; 2.3.3 Chemotherapy combinations; 2.4 Study planning; 2.4.1 Sources for protocol ideas; 2.4.2 Choice of primary and secondary objectives; 2.4.3 Ways to speed protocol writing; 2.4.4 Inclusion and exclusion criteria; 2.4.5 Subject registration and accrual goals; 2.4.6 Evaluation schedule; 2.4.7 Treatment schedule; 2.4.8 Assessment of toxicity and reporting adverse events; 2.4.9 Scheme for dose modification; 2.4.10 Data collection and documentation.
|
| 505 |
8 |
|
|a 2.5 The protocol review process2.6 Funding and budgeting; 2.7 Enhancing protocol accrual; References; Chapter 3 Clinical trials of image-guided interventions including radiotherapy studies ; 3.1 Introduction; 3.2 Establishing the context for IGI clinical trials; 3.2.1 Clinical utilities; 3.2.2 Translational continuum; 3.2.3 Why do IGI clinical trials differ from other therapy or imaging trials?; 3.3 A paradigm for considering IGI clinical trial design; 3.4 Radiotherapy trials; 3.4.1 Preclinical radiotherapy studies; 3.4.2 Phase I radiotherapy studies; 3.4.3 Phase II/III radiotherapy studies.
|
| 505 |
8 |
|
|a 3.5 Caveats in the design and conduct of IGI trials3.5.1 Defining the clinical trial cohort; 3.5.2 Standardization of the study procedures and quality assurance; 3.5.3 IGI trial QA; 3.5.4 IGI clinical trial endpoints: measures of success and failure; 3.6 Potential impediments to the design and conduct of IGI clinical trials; 3.6.1 Evaluation of the placebo effect; 3.6.2 Masking or blinding of investigators; 3.6.3 Impediments related to "standard of care" control interventions; 3.6.4 Rapid evolution of the IGI device and related devices: multiple similar competitive IGI devices.
|
| 505 |
8 |
|
|a 3.6.5 The feasibility of RCTs of IGIs3.6.6 Impediments to and pitfalls in the conduct of the trial; 3.7 Special considerations and the future; 3.7.1 Conclusion; References; CHAPTER 4 Imaging as a predictor of therapeutic response; 4.1 Introduction; 4.1.1 What is a biomarker?; 4.1.2 Why do we need imaging biomarkers to direct therapy?; 4.1.3 Types of therapeutic biomarkers; 4.2 Imaging- versus tissue-based biomarkers ; 4.3 Examples of imaging biomarker applications; 4.3.1 Prognostic markers; 4.3.2 Predictive markers; 4.3.3 Early response markers.
|
| 500 |
|
|
|a 4.3.4 Therapeutic benefit markers and surrogate measurements for long-term outcomes.
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Diagnostic imaging.
|
| 650 |
|
0 |
|a Clinical trials.
|
| 650 |
|
2 |
|a Diagnostic Imaging
|
| 650 |
|
2 |
|a Clinical Trials as Topic
|
| 650 |
|
6 |
|a Imagerie pour le diagnostic.
|
| 650 |
|
6 |
|a Études cliniques.
|
| 650 |
|
7 |
|a Clinical trials
|2 fast
|
| 650 |
|
7 |
|a Diagnostic imaging
|2 fast
|
| 700 |
1 |
|
|a Gazelle, G. Scott.
|
| 758 |
|
|
|i has work:
|a Handbook for clinical trials of imaging and image-guided interventions (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCG8P3r8tB8wfWbtmTKP84q
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Obuchowski, Nancy A.
|t Handbook for Clinical Trials of Imaging and Image-Guided Interventions.
|d : Wiley, ©2015
|z 9781118849712
|
| 856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=4306426
|z Texto completo
|
| 938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL4306426
|
| 938 |
|
|
|a Recorded Books, LLC
|b RECE
|n rbeEB00659281
|
| 994 |
|
|
|a 92
|b IZTAP
|
